On September 30, 2020, the Third Circuit reversed a decision by the Eastern District of Pennsylvania ordering AbbieVie, Inc. (“AbbieVie”) and Besins Healthcare Inc. (“Besins”) to pay $448 million in disgorgement of ill-gotten profits for allegedly filing sham patent lawsuits to stifle competition. AbbieVie and Besins had filed patent infringement lawsuits against two developers of generic alternatives to its brand-name testosterone gel product AndroGel. The FTC sued AbbieVie and Besins in 2014 alleging that the patent suits were baseless and brought for no other ...
Blog Editors
Recent Updates
- State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
- The DOJ’s New Corporate Enforcement Policy: A Familiar but Now Nationally Unified Framework for Voluntary Self-Disclosure
- The Case Was Settled, but ChatGPT Thought Otherwise: A Dispute Poised to Define AI Legal Liability
- “Claude Is Not an Attorney”: Individuals Risk Abandoning the Attorney-Client Privilege and Attorney Work-Product Doctrine When Consulting AI
- Prediction Markets v. State Gaming Laws: The Kalshi Litigation Gamble